ArticleGland surgery2021
The immune-related gene CD52 is a favorable biomarker for breast cancer prognosis.
Article in Gland surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Inference of marker genes of subtle cell state changes via iLR: iterative logistic regression.Bioinformatics (Oxford, England) · 2026Article
- CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy.NPJ breast cancer · 2026Article
- Robust and interpretable prediction of gene markers and cell types from spatial transcriptomics data.Nature communications · 2026Article
- Elevated NUF2 and CD52 expression predict platinum-based chemoresistance and poor prognosis in non-small cell lung cancer.Discover oncology · 2025Article
- N7-methylguanosine (m7G) modification in breast cancer: clinical significances and molecular mechanisms.Cancer cell international · 2025Review
- Multi-Omics Pan-Cancer Profiling ofBiology · 2025Article
- Responses to checkpoint inhibition in metastatic triple negative breast cancer driven by divergent myeloid phenotypes.Communications medicine · 2025Article
- Immunogenic cell death-related genes as prognostic biomarkers and therapeutic insights in uterine corpus endometrial carcinoma: an integrative bioinformatics analysis.Frontiers in oncology · 2025Article
- Canine mammary tumors as a promising adjunct preclinical model for human breast cancer research: similarities, opportunities, and challenges.Archives of pharmacal research · 2025Review
- A spatiotemporal comparative analysis on tumor immune microenvironment characteristics between neoadjuvant chemotherapy and preoperative immunotherapy for ESCC.Cell death & disease · 2024Article
- Integrating single-cell transcriptomics and machine learning to predict breast cancer prognosis: A study based on natural killer cell-related genes.Journal of cellular and molecular medicine · 2024Article
- Article
- Leveraging a disulfidptosis-related signature to predict the prognosis and immunotherapy effectiveness of cutaneous melanoma based on machine learning.Molecular medicine (Cambridge, Mass.) · 2023Article
- Prognostic and immune implications of a novel 7-methylguanosine-related microRNA signature in breast invasive carcinoma: from exploration to validation.Journal of cancer research and clinical oncology · 2023Article
- Shedding light on macrophage immunotherapy in lung cancer.Journal of cancer research and clinical oncology · 2023Review
- [CD40LG is a novel immune- and stroma-related prognostic biomarker in the tumor microenvironment of invasive breast cancer].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- Enhancing progestin therapy via HDAC inhibitors in endometrial cancer.American journal of cancer research · 2022Article
- Using immune-related lncRNAs to construct novel biomarkers and investigate the immune landscape of breast cancer.Translational cancer research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn increasing number of studies have demonstrated a role for the tumor microenvironment in tumorigenesis, disease progression, and therapeutic response. This present study aimed to screen the significant immune-related genes and their possible role in the prognosis of breast cancer (BRCA).
methodsThe transcriptome data and clinical data of breast cancer were collected from The Cancer Genome Atlas (TCGA), and the immune scores and stromal scores were calculated by ESTIMATE algorithm. The differentially expressed genes were screened base on immune and stromal scores (high score
resultsHigh levels of CD52 expression were detected in the early stages of breast cancer and were associated with favorable prognosis. Overexpression of CD52 led to higher infiltrations of M1 macrophages, monocytes, T follicular helper cells, and resting memory CD4 T cells. Downregulation of CD52 resulted in high infiltrations of M2 macrophages. Therefore, high expression of CD52 may negatively regulate the infiltration of M2 macrophages but accelerate the infiltration of anti-cancer immune cells, and thus, high expression of CD52 may have a protective effect in breast cancer patients.
conclusionsCD52 can increase the infiltration of anti-cancer immune cells but inhibit the infiltration of M2 macrophages, thereby improving the prognosis of breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.